Swine flu pandemic linked to increased incidence of diabetes
September 19, 2017Manufacturing and Production, Research and Development biotech, diabetes type 1, drugs, influenza, pharma, pharmaceutical, swine flu
The swine flu pandemic that swept the world in 2009 may have had unforeseen consequences in some populations, after researchers …
Scholar Rock prise Regulatory Affairs director away from Biogen
September 18, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scholar Rock, biotech, drugs, pharma, pharmaceutical
Scholar Rock has announced that it has moved to appoint Heather Faulds as Vice President of Regulatory Affairs. Faulds joins …
Novartis’ Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria
September 18, 2017Research and Development, Sales and Marketing Novartis, Xolair, chronic spontaneous urticarial, pharma, pharmaceutical
Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …
Standing together: Supercharging the clinical trial in Europe
September 18, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, biotech, clinical trials, drugs, pharma, pharmaceutical
The European Medicines Agency is on the cusp of rolling out one of the most ground-breaking digital platforms for facilitating …
FDA approves first medical app, for use in addiction
September 18, 2017Sales and Marketing Pear Therapeutics, biotech, drugs, pharma, pharmaceutical, reset
The FDA has taken a major step in the digitisation of healthcare by handing out the first medical app approval: …
China’s Fosun Group grabs 74% stake in India’s Gland Pharma for $1.1 billion
September 18, 2017Sales and Marketing China, Fosun Pharma, Gland Pharma, India, pharma, pharmaceuticals
Chinese conglomerate Fosun has agreed to acquire 74% of India’s Gland Pharma for $1.1 billion, sealing a previously unsuccessful deal …
Bayer lymphoma treatment speeds to FDA approval
September 18, 2017Sales and Marketing Aliqopa, Bayer, biotech, drugs, pharma, pharmaceutical
The FDA gave Bayer priority review for its treatment Aliqopa (copanlisib) in May of this year, and it quickly came …
Santhera ‘surprised’ by European rejection of DMD drug
September 18, 2017Sales and Marketing Duchenne Muscular Dystrophy, biotech, drugs, pharma, pharmaceutical, santhera
Santhera Pharmaceutical has announced the EMA’s CHMP rejected its treatment for Duchenne muscular dystrophy (DMD) but revealed that it planned …
Top Ten most popular articles on Pharmafile.com this week
September 15, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten
This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …
Pfizer receives prostate cancer drug boost with trial results
September 15, 2017Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical
Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …
FDA approves first-ever biosimilar for cancer treatment
September 15, 2017Medical Communications, Sales and Marketing Amgen, Cancer, FDA, Mvasi, avastin, biosimilar
The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer …
GSK receives positive opinion for triple-therapy inhaler
September 15, 2017Medical Communications, Sales and Marketing GSK, biotech, drugs, pharma, pharmaceutical
GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
Recipharm and Kancera collaborate to manufacture clinical trial supply
September 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm
Recipharm, a leading contract development and manufacturing organisation (CDMO) and Kancera, a development company focused on cancer therapy, have signed …
AstraZeneca’s Forxiga displays potential in type 1 diabetes
September 14, 2017Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical
Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
GDPR and Human Data Samples: Being ‘somewhat prepared’ is not enough
September 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GDPR, biotech, data, drugs, pharma, pharmaceutical
Thomas Hirse, Partner, and Paetrick Sakowski, Associate, CMS, discuss what pharmaceutical companies need to be aware of ahead of the …
FDA panel gives GSK’s Shingrix unanimous approval
September 14, 2017Sales and Marketing GSK, Shingrix, biotech, drugs, pharma, pharmaceutical, shingles
The FDA’s advisory panel has given a strong signal that GSK’s Shingrix should not have too much difficulty getting full …
Novo’s Xultophy beats basal insulin in cutting cardiovascular risk
September 14, 2017Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …
‘Pharma bro’ Shkreli heads to jail
September 14, 2017Medical Communications Martin Shkreli, Shkreli, biotech, drugs, pharma, pharmaceutical
Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that …
Amicus pulls plug on rare skin disease drug after Phase 3 failure
September 14, 2017Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure
New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
